Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 127 | 1 | 129 | +3 |
| Shares | 109.4M | 29 | 97.8M | −11.6M (−10.6%) |
| Value | $49.7M | $13 | $88.4M | +$38.7M (+77.8%) |
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (35)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
Sold out (32)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
Not filed for Q2 2025 yet (1)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Lindbrook Capital, LLC | 29 | $13 |